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Helminthic infections
Shally Awasthi, D A P Bundy, Lorenzo Savioli
Parasitic worms have largely been overlooked by medicine, but attitudes are changing with the
realisation that they can seriously affect child development and that treatment is easy and cheap
Parasitic worms do not usually interest doctors
because, although worms can cause severe clinical dis-
ease, they usually have insidious effects on growth and
development that rarely cause attendance at health
centres. Yet it is precisely these chronic effects, affecting
more than two billion people with lifelong infections,
that have forced the public health community to reas-
sess the importance of these infections. And recogni-
tion of the simplicity, safety, low cost, and efficacy of
treatment has now resulted in major global initiatives
to achieve control.
Methods
Information for this review came from Medline and
hand searches of published literature, correspondence
with experts in the subject, and the personal
experiences of the authors.
Size of the problem
Parasitic worms may be the commonest cause of
chronic infection in humans. In many low income
countries it is more common to be infected than not.
Indeed, a child growing up in an endemic community
can expect be infected soon after weaning, and to be
infected and constantly reinfected for the rest of her or
his life.
There are about 20 major helminth infections of
humans, and all have some public health significance,1
but among the commonest of all human infections are
the geohelminthiases. Recent global estimates indicate
that more than a quarter of the world’s population are
infected with one or more of the most common of
these parasites—the roundworm, Ascaris lumbricoides;
the hookworms, Necator americanus and Ancylostoma
duodenale; and the whipworm, Trichuris trichiura.2
About 85% of the 200 million people with schisto-
somiasis live on the African continent,3 70 million
people have haematuria associated with Schistosoma
haematobium infection, and the two commonest species
together contribute to the deaths of more than a quar-
ter of a million people a year from complicated neph-
rosis and portal hypertension.4 Hookworm infection is
the leading cause of pathological blood loss in tropical
and subtropical regions.5 Some 44 million pregnancies
are currently complicated by maternal hookworm
infection,6 placing both mothers and children at higher
risk of death during pregnancy and delivery.
All worm infections are not equal
The distribution of helminths among hosts is
overdispersed: that is, while most hosts harbour few or
no worms, a few harbour many parasites.7 This
distribution has clinical consequences for hosts, as it is
mainly the intensity of infection that determines the
severity of morbidity.8 9 Infection with Trichuris trichiura
and Ascaris lumbricoides typically reaches maximum
intensity at 5-10 years of age, after which it declines to
a lower level that then persists throughout adulthood
(figure).1 A similar profile is apparent for Schistosoma
infections, but with maximum intensity attained at a
slightly later age, usually 10-14 years. A different profile
is apparent for hookworm infections, with maximum
intensity usually not attained until 20-25 years.8
Children of school age are thus particularly at risk
from the clinical manifestations of disease. Indeed, it
has been estimated that, for children aged 5-14 years in
low income countries, intestinal worms account for
12% of the total disease burden. About 20% of disabil-
ity adjusted life years (DALYs) lost due to communica-
ble disease among school children are a direct result of
intestinal nematodes.10 In 1999 the World Health
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Organization estimated that these infections repre-
sented more than 40% of the disease burden from all
tropical diseases excluding malaria.
Effects of worm infections on child
growth and development
By far the most common effect on health is a subtle
and insidious constraint on normal physical develop-
ment, resulting in children failing to achieve their
genetic potential for growth and having the clinical
consequences of iron deficiency anaemia and other
nutritional deficiencies. Heavy hookworm burdens
have long been recognised as an important cause of
iron deficiency anaemia.11 Intense whipworm infection
in children may result in trichuris dysentery syndrome,
the classic signs of which include growth retardation
and anaemia,12 and heavy burdens of both roundworm
and whipworm are associated with protein energy
malnutrition.13
Medium and large scale control programmes have
clearly shown that morbidity from these infections can
be significantly reduced through repeated and regular
treatment with single dose anthelmintics delivered
through school health programmes or other ongoing
health or education programmes.14 15 Several control-
led trials have shown that treatment has a positive
effect on growth, although the extent of benefit gained
has varied.16–18
Learning and education
Given the prevalence of high intensity infection in
schoolchildren, it is particularly worrying that these
infections can adversely affect cognition and edu-
cational achievement.19 The mechanism by which
mental processes are affected is uncertain, but
evidence suggests that the mechanism is indirect,
perhaps mediated through iron deficiency anaemia
and undernutrition.20
Whether helminth infections directly cause cogni-
tive deficits is a matter of debate. In one analysis, the
majority of 40 studies showed an association between
geohelminthic infection and impaired cognitive or
educational abilities,21 but few of these studies were well
designed. Studies often show an effect in the most
heavily infected children, but with such mixed results it
has been difficult to reach any strong conclusions as to
whether helminthiases directly contribute to impaired
cognitive functioning.16
Recently, more comprehensive studies have used
newmeasures of learning ability to detect the impact of
infection. In Tanzania schoolchildren most heavily
infected with worms achieved significantly lower scores
in some tests of cognitive ability,22 but eradication treat-
ment did not result in an immediate improvement in
the children’s ability to conduct these tests. However,
when children were both treated and taught how to do
cognitive tests they performed significantly better than
children who were taught but not treated.23 These
results suggest that children with chronic infection, and
the constrained development that results from this, will
need not only improved health but also a good educa-
tion to catch up.
School based deworming programmes also boost
school participation. In Kenya, such a programme
reduced school absenteeism by a quarter, with the
largest gains among the youngest children.24 Perhaps
even more importantly, this study showed that those
children who had not been treated benefited from the
generally lowered transmission rate in the schools. The
overall outcome was that an extra year of schooling
could be obtained for an investment of some $4 (£2.50,
€2.80) per child per year—a remarkable return on
investment.
Treatment
Treatment of a child with praziquantel for schisto-
somiasis currently costs about 20 cents. A single dose
treatment for soil transmitted helminth infections with
any of the four anthelmintics on the WHO list of
essential drugs (albendazole, levamisole, mebenda-
zole, and pyrantel) costs less than 3 cents. WHO has
calculated that the cost of intervention, including
delivery, where schistosomiasis and soil transmitted
helminth infections are endemic is typically less than
$1 and can be as low as 30 cents per child per year,
while treatment of soil transmitted helminth infec-
tions alone costs as little as 10 cents per child per
year.25
Many of the technical problems associated with
large scale treatment campaigns have been addressed
and solved. For example, teachers and other people
who are not health professionals can distribute
anthelmintic drugs effectively to school age children
with minimal training.26 27 Community treatment may
be simplified by the use of a “dose pole”—which deter-
mines the correct dose from a child’s height.28–30 Prazi-
quantel treatment should also be offered to pregnant
women with schistosomiasis, as the benefits of such
treatment greatly outweigh any reported adverse
effects.31 Mebendazole, albendazole, and other
anthelmintics have also recently been approved for use
in children over 12 months old.31
Not only children can benefit from treatment. In
Sierra Leone anthelmintic treatment had an additive
effect when combined with iron and folate supple-
ments to control maternal anaemia during pregnancy.5
In Sri Lanka the same combined intervention
improved the health of mothers, with a beneficial effect
on their birth outcome without any increased risk of
malformations.32 33
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Support for treatment programmes
Delivering treatment through the education sector
In April 2000, at the Dakar World Education Forum, a
partnership was launched by Unesco, Unicef, WHO,
Education International, and the World Bank to help
countries in “Focusing Resources on Effective School
Health,” including support for the distribution of
anthelmintics through schools.34 This “FRESH” partner-
ship aims to improve the health and nutrition of school-
children as a contribution to the global “Education for
All” efforts to ensure universal access to basic education.
To date, more than 20 projects targeting 45 million chil-
dren of school age have been supported in Africa.
Supporting schistosomiasis control
In July 2002 the Bill and Melinda Gates Foundation
gave a $30m grant to Imperial College, London, to
support a schistosomiasis control initiative. This initia-
tive is working with partners to ensure that treatment is
available for young people, especially schoolchildren,
and women and all those at particular risk through
their work. The initiative aims to provide 35 million
doses for both schistosomiasis and intestinal nematode
infection to some 20 million people in Africa over the
next five years, and to assist countries in making the
transition to self sustained programmes.
A new partnership to boost global efforts
The 54th World Health Assembly resolution set a
global target of scaling up intervention to regularly
treat 75% of school age children at risk (398 million) by
2010. To achieve this, WHO has developed a broad
partnership that promotes the incorporation of
deworming into existing institutions and programmes,
for both the education and health sectors. The Partner-
ship for Parasite Control was launched in 2001 with
the aim of mobilising resources and promoting new
synergy among public and private efforts for the
control of soil transmitted helminths and schisto-
somiasis at global and national levels. Working with the
World Food Programme and the World Bank,WHO in
2001 trained representatives of the ministries of health
and education of 21 countries, and deworming
programmes have begun in 19 of the 41 African coun-
tries where infections are endemic.
The dangers of drug resistance
Expanding treatment programmes increases the drug
pressure on parasite populations. The evidence for the
emergence of drug resistance in human helminthes is
equivocal, despite the long term widespread use of
anthelmintics. Nevertheless, the risk of drug resistance
is real. To prevent or delay the emergence of resistance
treatment should be targeted only to high risk groups
such as schoolchildren, which ensures gene flow
among a worm population without drug pressure, and
delivered infrequently, typically no more frequently
than every 6 months. Monitoring and surveillance of
drug efficacy is being built into operational pro-
grammes.35
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